




(86) Date de dépôt PCT/PCT Filing Date: 2003/08/11
(87) Date publication PCT/PCT Publication Date: 2004/03/04
(85) Entrée phase nationale/National Entry: 2005/02/07
(86) N° demande PCT/PCT Application No.: IB 2003/003582
(87) N° publication PCT/PCT Publication No.: 2004/018484
(30) Priorité/Priority: 2002/08/23 (60/405,640) US

(51) Cl.Int.⁷/Int.Cl.⁷ C07D 499/00, A61K 31/43, A61P 31/04
(71) Demandeur/Applicant:
PFIZER PRODUCTS INC., US
(72) Inventeurs/Inventors:
MARFAT, ANTHONY, US;
MCLEOD, DALE GORDON, US
(74) Agent: SIM & MCBURNEY

(54) Titre : PROMEDICAMENT INHIBITEUR DE BETA-LACTAMASE
(54) Title: BETA-LACTAMASE INHIBITOR PRODRUG



(57) **Abrégé/Abstract:**

Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention, or a solvate thereof, an optional beta-lactam antibiotic and at least one pharmaceutically acceptable carrier. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a betalactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018484 A1

(51) International Patent Classification⁷: **C07D 499/00**,
A61K 31/43, A61P 31/04

(74) Agents: **LUMB, J., Trevor et al.**; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(21) International Application Number:
PCT/IB2003/003582

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 11 August 2003 (11.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/405,640 23 August 2002 (23.08.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **MAREFAT, Anthony** [US/US]; Pfizer Global Research And Development, Eastern Point Road, Groton, CT 06340 (US). **MCLEOD, Dale, Gordon** [CA/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BETA-LACTAMASE INHIBITOR PRODRUG



(I)

(57) Abstract: Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention, or a solvate thereof, an optional beta-lactam antibiotic and at least one pharmaceutically acceptable carrier. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a betalactam antibiotic and an effectiveness-increasing amount of

a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.

WO 2004/018484 A1

BETA-LACTAMASE INHIBITOR PRODRUG

BACKGROUND OF THE INVENTION

Beta-lactam antibiotics, which generally are penicillins and cephalosporins, have been widely used in the treatment of infections, primarily bacterial, in mammals such as man. Certain micro-organisms are believed to be resistant to these antibiotics because they produce various beta-lactamase enzymes which attack the beta-lactam ring of the antibiotic thereby rendering the drug ineffective.

In U.S. Patent No. 4,287,181, Kellogg disclosed that various 6 β -hydroxyalkylpenicillanic acids, including 6- β -hydroxymethylpenicillanic acid sulfone which is the beta-lactamase inhibitor used in the present invention, are potent beta-lactamase inhibitors. U.K. Patent Application GB2053220A, Metzger *et al.* and U.K. Patent Application GB2076812, by Schneider *et al.*, likewise disclosed that 6- β -hydroxymethyl-penicillanic acid sulfone is a beta-lactamase inhibitor. However, the beta-lactamase inhibitor 6- β -hydroxymethyl-penicillanic acid sulfone is very poorly absorbed *in vivo* in rodents during preclinical studies when administered orally.

Kellogg, Metzger *et al.* and Schneider *et al.* also disclosed ester prodrugs of 6- β -hydroxymethylpenicillanic acid sulfone, which readily hydrolyze *in vivo*, during preclinical studies, and which demonstrated better absorption in rodents than did the free acid.

5 However, many of these ester prodrugs could only be
synthesized as oils or as solids that had low melting
points whose usefulness in pharmaceutical formulations
is more limited than would be a solid prodrug with a
melting point suitable for tableting, milling or
10 purification.


 Furthermore, these ester prodrugs were typically
not highly absorbed when orally administered. Thus,
higher drug dosages would be required to be administered
orally, to obtain a therapeutically effective plasma
15 level of the beta-lactamase inhibitor 6- β -
hydroxymethylpenicillanic acid sulfone, than would be
required for a more highly absorbed prodrug. In
addition, oral administration of the less absorbed
prodrugs may result in an increase in the incidence and
20 severity of diarrhea experienced by the recipient as the
unabsorbed prodrug may hydrolyze in the gastro-
intestinal tract, to form the active drug, and, with any
residual amoxicillin, selectively kill essential
components of the normal microbial flora. Further, it
25 is desirable that the process, for producing the desired
prodrug, be relatively inexpensive.

 Therefore, there is a need for a crystalline
prodrug of the beta-lactamase inhibitor 6- β -
hydroxymethylpenicillanic acid sulfone which has a high
30 oral bioavailability, and more preferably is crystalline
with a suitable melting point.

SUMMARY OF THE INVENTION

 The present invention relates to prodrugs of 6- β -
35 hydroxymethylpenicillanic acid sulfone (also named 4-

5 thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide (2S,5R,6R)) having the structure




10

and solvates thereof, wherein R is H or methyl. The prodrugs of the present invention include 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-methyl ester, 4,4-dioxide (2S,5R,6R);

4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)-ethyl ester, 4,4-dioxide (2S,5R,6R); 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R); and 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R). The preferred prodrug of the present invention is 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), which has the structure

30



5

or a solvate thereof.

The present invention also relates to pharmaceutical compositions comprising a prodrug of the present invention, or a solvate thereof, an optional
 10 beta-lactam antibiotic and at least one pharmaceutically acceptable carrier, excipient or diluent. Preferably, the beta-lactam antibiotic is amoxicillin. It is also preferred that the prodrug, used in the pharmaceutical composition, is 4-thia-1-azabicyclo[3.2.0] heptane-2-
 15 carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a solvate thereof. It is more preferred that the pharmaceutical composition comprises 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 6-
 20 (hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a solvate thereof, amoxicillin and a pharmaceutically acceptable carrier, excipient or diluent.

The present invention further relates to a method
 25 for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal comprising administering to said mammal an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof.
 30 Preferably, the beta-lactam antibiotic is amoxicillin. It is also preferred that the prodrug used is 4-thia-1-

5 azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a solvate thereof. It is more preferred that the prodrug is 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic
10 acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a solvate thereof, and the beta-lactam antibiotic is amoxicillin. It is further preferred that the mammal is a human.

15 The present invention additionally relates to the treatment of a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof. Preferably, this pharmaceutical
20 composition further comprises a beta-lactam antibiotic. Preferably, the beta-lactam antibiotic is amoxicillin. It is also preferred that the prodrug used is 4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) or a
25 solvate thereof. It is more preferred that the prodrug is 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or a
30 solvate thereof, and the beta-lactam antibiotic is amoxicillin. It is further preferred that the mammal is a human.

5 DETAILED DESCRIPTION

The terms used to describe the present invention have the following meanings herein.

10 The term "effective amount" means the amount of beta-lactam antibiotic which, when administered either alone, or in combination with a prodrug of the present invention which prevents the onset of, alleviates the symptoms of, stops the progression of, or eliminates a bacterial infection in a mammal.

15 The term "effectiveness-increasing amount" means that amount of prodrug which, when administered to a mammal and which subsequently hydrolyzes *in vivo* to form the beta-lactamase inhibitor of the present invention, increases the therapeutic effectiveness of a co-administered beta-lactam antibiotic.

20 The term "mammal" is an individual animal that is a member of the taxonomic class Mammalia. The class Mammalia includes, for example, humans, monkeys, chimpanzees, gorillas, cattle, swine, horses, sheep, dogs, cats, mice and rats.

25 In the present invention, the preferred mammal is a human.

The term "pharmaceutically acceptable" means that the carrier, diluent and excipients must be compatible with other ingredients of the composition, and not
30 deleterious to the recipient thereof. Pharmaceutical compositions of the present invention are prepared by procedures known in the art using well known and readily available ingredients.

The prodrugs of the present invention include 4-
35 thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-

5 (hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-
(benzoyloxy)methyl ester, 4,4-dioxide (2S,5R,6R) which
is described in Example 3 and 4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl
110 ester, 4,4-dioxide (2S,5R,6R) which is described in
Example 4.

The prodrugs of the present invention, as further
described in Example 7, are stable in the upper GI tract
but, after absorption, readily hydrolyze *in vivo* to form
15 6- β -hydroxymethylpenicillanic acid sulfone (hereinafter
know as "6- β -HMPAS") which is a beta-lactamase inhibitor
that increases the effectiveness of beta-lactam
antibiotics against beta-lactamase-producing bacteria.
This beta-lactamase inhibition preserves the
20 antibacterial potency of a co-administered beta-lactam
antibiotic against beta-lactamase (+) strains.

As the prodrugs of the present invention hydrolyze
in vivo and form the free acid beta-lactamase inhibitor
6- β -HMPAS, these prodrugs are useful in that, when
25 administered to a mammal, the effectiveness of a co-
administered beta-lactam antibiotic against beta-
lactamase producing bacteria will be enhanced.

Prodrugs of this invention may be used, in
combination therapy with beta-lactam antibiotics, to
30 treat infections of, for example, the respiratory tract,
the urinary tract and soft tissues in humans.
Compositions of this invention may also be used to treat
infections in other mammals, such as mastitis in cattle.

Bacterial infections amenable to treatment by the
35 prodrug, pharmaceutical composition and method of the

5 present invention include upper respiratory diseases including community acquired pneumoniae (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS), caused by respiratory pathogens, such as *Haemophilus influenzae* and *Moraxella*
10 *catarrhalis* including antibiotic resistant isolates.

Further, bacterial infections amenable to treatment, by pharmaceutical compositions of the present invention which contain an antibiotic, include, in particular, pediatric otitis media, sinusitis,
15 pneumonia and acute exacerbations of bronchitis in adults caused by *H. influenzae* or *Streptococcus pneumoniae*, including Drug Resistant *S. pneumoniae* (DRSP) such as Penicillin Resistant *S. pneumoniae*.

Additional, bacterial infections amenable to treatment, by pharmaceutical compositions of the present invention which contain an antibiotic, include, soft tissue infections caused by *E. Coli*, *Klebsiella pneumoniae*, *Enterobacter spp.* and all other members of the family *Enterobacteriaceae*.

25 Other infections amenable to treatment, by pharmaceutical compositions of the present invention which contain an antibiotic, including those caused by beta-lactamase producing methicillin susceptible *staphylococci* and beta-lactamase producing anaerobes.

30 As the prodrugs of the present invention contain more than one chiral center, they exist in different optically active diastereomeric forms. More specifically, the preferred prodrugs of the present invention contain a chiral center at the 1-ethyl
35 location. The present invention includes both 1R and 1S

5 diastereomers of 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), and also includes, and mixtures of these diastereomers, such as racemic mixtures. These diastereomeric forms, a
10 mixture thereof, and their respective syntheses are further described herein in the following Examples 4-6.

Even more preferably, the prodrug of the present invention comprises the 1R diastereomer of 4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid, 6-
15 (hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) as is described in Example 5.

The prodrugs of the present invention may exhibit polymorphism. Polymorphs of prodrugs form part of this
20 invention and may be prepared by crystallization of a prodrug of the present invention under different conditions. For example, using different solvents or different solvent mixtures for recrystallization; crystallization at different temperatures; various modes
25 of cooling ranging from very fast to very slow cooling during crystallization. Polymorphs may also be obtained by heating or melting a prodrug followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe nmr spectroscopy, ir
30 spectroscopy, differential scanning calorimetry, powder X-ray diffraction or other such techniques.

The prodrugs of the present invention may also exist in the form of solvates, for example, hydrates. The present invention includes each solvate and mixtures
35 thereof.

5 For a prodrug, the minimum amount of prodrug administered is that amount which will increase the effectiveness of a co-administered beta-lactam antibiotic. The maximum amount of prodrug administered is that amount, which either alone or in combination
10 with the beta-lactam antibiotic, is toxicologically acceptable.

Typically, for adults and children weighing at least 40 kg, the daily dosage amount of prodrug is between about 200 mg to about 1 g or more. For children
15 weighing less than 40 kg, the daily dosage amount of prodrug is between about 7 mg/kg/day to about 20 mg/kg/day or more. However, these figures are illustrative only, and, in some cases, it may be necessary to use dosages outside these limits.

20 A daily dosage of the prodrug of the present invention can be administered from 1 to 4 times daily in equal doses.

In the treatment of a bacterial infection, a prodrug of the present invention is co-administered with
25 a beta-lactam antibiotic. The prodrug and the beta-lactam antibiotic may be administered concurrently or sequentially. Further, the prodrug and antibiotic may be contained in separate pharmaceutical compositions or in a single pharmaceutical composition.

30 Typical beta-lactam antibiotics, with which the prodrug of the present invention is co-administered, are beta-lactam antibiotics which are sensitive to enzymatic degradation and inactivation by various beta-lactamase enzymes. Examples of such beta-lactamase sensitive
35 antibiotics include, but are not limited to, penicillins

5 such as natural penicillins, amoxicillin and ampicillin;
cephalosporins such as cefadroxil, cefazolin,
cephalexin, cephalothin, cephapirin, cephradine,
cefaclor, cefamandole, cefoicid, ceforanide, cefprozil,
cefuroxime, cefdinir, cefoperazone, cefotaxime,
10 cefpodoxime, ceftazidime, ceftibuten, ceftizoxime,
ceftriaxone and cefepime; and monobactams such as
aztreonam.

Typically, when contained together in a
pharmaceutical composition, the weight ratio of beta-
15 lactam antibiotic to prodrug is between about 15:1 to
about 1:1.

Preferably, a prodrug of the present invention is
co-administered with amoxicillin. More preferably,
amoxicillin is co-administered with the prodrug 4-thia-
20 1-azabicyclo[3.2.0]-heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R).

The term "amoxicillin" as used herein shall mean
amoxicillin or an alkaline salt, or hydrate thereof such
25 as in particular amoxicillin trihydrate or
(crystallized) sodium amoxicillin. Unless otherwise
indicated, weights of amoxicillin refer to the
equivalent weight of the corresponding free acid. In
addition, it will be appreciated that in practice,
30 weights of amoxicillin to be incorporated into a
formulation will be further adjusted, in accord with
conventional practice, to take account of the potency of
the amoxicillin.

Typically, an effective amount of amoxicillin, for
35 adults and children weighing at least 40 kg, is a daily

5 dosage level of about 250 mg to about 5 g. For children weighing less than 40 kg, an effectiveness-increasing amount of amoxicillin is a daily dosage level of about 20 mg/kg/day to about 150 mg/kg/day. However, these figures are illustrative only, and, in some cases, it
10 may be necessary to use dosages outside these limits.

A daily dosage of amoxicillin can be administered from 1 to 4 times daily in equal doses in the form of immediate, modified or delayed (or slow) release compositions. Formulations of immediate, modified and
15 delayed (slow) release pharmaceutical compositions containing amoxicillin, which are suitable for the pharmaceutical composition of the present invention, and the preparation thereof, are described in United States Patent Nos. 4,537,887, issued to Rooke et al.,
20 6,051,255, issued to Conley et al., 6,218,380, issued to Cole et al., 6,051,255, issued to Conley et al.; United States Patent Application Serial Number 09/911,905, by Conley et al.; and International Application Number PCT/IB01/01899, by Conley et al. The teachings of U.S.
25 Patent Nos. 4,537,887, 6,051,255, 6,218,380, 6,051,255, USSN 09/911,905 and International Application Number PCT/IB01/01899 are incorporated herein, in their entirety, by reference.

In these compositions, the exact amount of prodrug
30 and amoxicillin will depend to some extent on the micro-organism which is being treated.

As will be appreciated by one skilled in the art, some of the beta-lactam compounds are effective when administered orally or parenterally, while others are
35 effective only when administered parenterally. When a

5 prodrug of the present invention is combined with a
parenterally administered beta-lactam antibiotic, a
pharmaceutical suitable for which is effective only on
parenteral administration, a combination formulation
suitable for parenteral use will be employed. When the
10 prodrug is to be combined with a beta-lactam antibiotic
which is effective orally or parenterally, combinations
suitable for either oral or parenteral administration
can be prepared. Additionally, it is possible to
administer preparations of the prodrug orally, while at
15 the same time administering a further beta-lactam
antibiotic parenterally; and it is also possible to
administer preparations of the prodrug parenterally,
while at the same time administering the further beta-
lactam antibiotic orally.

20 A pharmaceutical composition, of the present
invention, comprises a prodrug of the present invention
and at least one pharmaceutically acceptable excipient,
carrier or diluent.

Optionally, the pharmaceutical composition further
25 comprises a beta-lactam antibiotic. It is preferred
that the antibiotic be amoxicillin. It is also
preferred that the prodrug is 4-thia-1-azabicyclo-
[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-
dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-
30 dioxide (2S,5R,6R). It is more preferred that the
pharmaceutical composition comprises 4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R),

5 amoxicillin and at least one pharmaceutically acceptable carrier.

Examples of excipients, diluents, and carriers that are suitable for such pharmaceutical compositions include: fillers and extenders such as starch, sugars,
10 mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as agar agar, calcium
15 carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and
20 lubricants such as talc, calcium and magnesium stearate and solid polyethylene glycols. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents
25 such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents.

In preparing a pharmaceutical composition of the present invention, the prodrug, and optional beta-lactam antibiotic, are usually mixed with an excipient, diluted
30 by an excipient or enclosed within a carrier that can be in the form of a capsule, sachet, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material that acts as a vehicle, carrier or medium for the active ingredient.

5 The pharmaceutical composition can be administered orally or parenterally, i.e. intramuscularly, subcutaneously, intravenously or intraperitoneally. The carrier, excipient or diluent is chosen on the basis of the intended mode of administration. For example, when
10 considering the oral mode of administration, a pharmaceutical composition of this invention can be used in the form of tablets including chewable tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like, in
15 accordance with standard pharmaceutical practice. The proportional ratio of active ingredient to carrier will naturally depend on the chemical nature, solubility and stability of the active ingredients, as well as the dosage contemplated. However, pharmaceutical
20 compositions containing a beta-lactam antibiotic and a prodrug of the present invention will preferably contain from about 20% to about 95% of active ingredients. In the case of tablets for oral use, carriers which are commonly used include lactose, sodium citrate and salts
25 of phosphoric acid. Various disintegrants such as starch, and lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular
30 weight polyethylene glycols. When aqueous solutions or suspensions are required for oral use, the active ingredient may be combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added. For parenteral
35 administration, sterile solutions of the active

5 ingredients are usually prepared, and the pH of the solutions is suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.

The formulations of the invention may be made up
10 into solid dosage forms for oral administration by a method conventional to the art of pharmaceutical technology, e.g. tablets or powder or granular products for reconstitution into a suspension or solution.

Suitable ingredients and suitable methods for
15 making such tablets are disclosed in, for example, International Applications WO 92/19227 and WO 95/28927 the teachings of which are incorporated herein, in their entirety, by reference. Powder or granular formulations, such as pediatric suspension formulations,
20 may be manufactured using techniques which are generally conventional in the field of manufacture of pharmaceutical formulations and in the manufacture of dry formulations for reconstitution into such suspensions. For example a suitable technique is that of
25 mixing dry powdered or granulated ingredients for loading into a suitable container.

For pediatric dosing, the formulations of the invention are preferably made up into a sweet flavored aqueous syrup formulation of generally conventional
30 formulation (except for its novel amoxicillin:prodrug ratio and intended use) containing a suitable weight of the amoxicillin and prodrug in a unit dose volume, e.g. 5 ml or 2.5 ml preferably as a syrup. A pediatric formulation may therefore comprise a bulk of a solution
35 or suspension, e.g. a syrup, or granules or powder which

5 can be made up into such a solution or suspension, at a
concentration of solution or suspension which contains
such a dose in such a volume. Suitable such formulations
are described in International application no PCT
EP96/01881 (SmithKline Beecham). The formulation of this
10 invention will normally, in addition to its active
materials amoxicillin and prodrug, also include
excipients which are standard in the field of
formulations for oral dosing and used in generally
standard proportions, and at generally standard particle
15 sizes and grades, etc.

In the case of pediatric oral suspensions, these
excipients may comprise suspending aids, glidants (to
aid filling), diluents, bulking agent, flavors,
sweeteners, and stabilizers.

20 Suitable excipients for use include xanthan gum
(suspension aid), colloidal silica (glidant), succinic
acid (stabilizer), aspartame (sweetener),
hydroxypropylmethylcellulose (suspension aid) and
silicon dioxide (diluent for prodrug and bulking agent).
25 Flavors may comprise common flavors such as bubble gum,
orange, banana, raspberry, grape and golden syrup, or
mixtures thereof, to suit local requirements.

The pharmaceutical composition of the present
invention may, for example, be provided in solid unit
30 dose forms embodying suitable quantities for the
administration of such a daily dose. For example a unit
dosage form may be tablets, or sachets containing
granules or powders for reconstitution, one or two of
which are to be taken 1-4 times daily. Alternatively a
35 unit dose may be provided as a bulk of solid or solution


5 or suspension, e.g. as a syrup for pediatric
administration, together with a suitable measuring
device of known type to facilitate administration of a
suitable unit dose quantity of the formulation. A
suitable unit dose quantity is one which enables the
10 administration of the above-mentioned daily dosage
quantity divided 1-4 doses.

Yet another embodiment of this invention is a kit,
for achieving an antibacterial therapeutic effect in a
mammal, comprising (1) a pharmaceutical composition,
15 which comprises a prodrug of the present invention and,
optionally, a beta-lactam antibiotic, and (2) directions
for the administration of the pharmaceutical composition
in a manner to achieve the desired therapeutic effect.

The present invention will be further illustrated
20 by means of the following examples. It is to be
understood, however, that the invention is not meant to
be limited to the details described therein.

Example 1

25 Preparation and Enantiomeric Separation of (R/S) Benzoic acid 1-chloro-ethyl ester




30

(R/S)-Benzoic acid 1-chloro-ethyl ester, shown
above, was prepared as follows.

5 To a stirred solution of 122 g (862 mmol.) benzoyl chloride (Aldrich), under a nitrogen atmosphere in a 3-neck round bottom flask, was added 2.35 g (17.2 mmol.) anhydrous zinc chloride (Aldrich). The reaction mixture was stirred for 15 minutes at room temperature and then
10 cooled to -15 °C using an ethylene glycol/ CO₂ bath. To this mixture was added slowly 37.9 g (862 mmol.) acetaldehyde (Aldrich) while maintaining an internal temperature below 0 °C. After addition was completed, the reaction mixture was allowed to warm to room
15 temperature. 400 mL water and 400 mL CH₂Cl₂ were added and then the layers were separated. The organic layer was separated and washed with saturated NaHCO₃, water, brine, dried over MgSO₄ filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1.75 %
20 ethyl acetate/ 98.25 % hexanes afforded 55.4 g of a yellow oil. ¹H-NMR (CDCl₃, 400 MHz): 8.08 (d, 2H, J=7.5Hz), 7.61 (t, 1H, J=7.5Hz), 7.47 (t, 2H, J=7.5Hz), 6.80 (q, 1H, J=6Hz), 1.93 (d, 3H, J=6Hz).

(R)-Benzoic acid 1-chloro-ethyl ester, shown below,
25 was isolated by the chiral separation of (+/-)-benzoic acid 1-chloro-ethyl ester using a 10 cm by 50 cm Chiralcel OJ column eluting with heptane/IPA (98/2) and with a flow rate of 250 mL/min. The enantiomer collected eluted second with an analytical purity
30 retention time of 7.123 min.




5

^1H -NMR (CDCl_3 , 400MHz): 8.08 (d, 2H, $J=7.5\text{Hz}$), 7.61 (t, 1H, $J=7.5\text{Hz}$), 7.47 (t, 2H, $J=7.5\text{Hz}$), 6.80 (q, 1H, $J=6\text{Hz}$), 1.93 (d, 3H, $J=6\text{Hz}$). $[\alpha_d] = -140^\circ$ ($C+0.0315$, CHCl_3).

10

(S)-Benzoic acid 1-chloro-ethyl ester, shown below, was isolated by the chiral separation of (+/-)-benzoic acid 1-chloro-ethyl ester using a 10 cm by 50 cm Chiralcel OJ column eluting with heptane/IPA (98/2) and with a flow rate of 250 mL/min. The enantiomer collected eluted first with an analytical purity retention time of 5.807 min.

15



20


^1H -NMR (CDCl_3 , 400MHz): 8.08 (d, 2H, $J=7.5\text{Hz}$), 7.61 (t, 1H, $J=7.5\text{Hz}$), 7.47 (t, 2H, $J=7.5\text{Hz}$), 6.80 (q, 1H, $J=6\text{Hz}$), 1.93 (d, 3H, $J=6\text{Hz}$). $[\alpha_d] = +130^\circ$ ($C+0.0345$, CHCl_3).

25

Example 2

Preparation of 4-Thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide, monosodium salt, (2S,5R,6R)

21




5

4-Thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid,
 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide,
 monosodium salt, (2S,5R,6R), shown above, (hereinafter
 10 "Na-HMPAS") was prepared by the following four-step
 process.

Step 1 - Preparation of sodium 6,6-dibromopenicillanate
sulfone

15




Ethyl acetate (15.8 L) was added to 6,6-
 dibromopenicil-lanic acid sulfone (2500 g) and heated to
 20 50 °C. Sodium ethyl hexanoate (1044 g) and ethyl acetate
 (5.0 L) were stirred to form a solution then added to
 the 6,6-dibromopenicillanic acid sulfone solution over a
 60 minute period. The reaction mixture was allowed to
 cool to ambient temperature and the resulting solids
 25 granulated for a period of 1 hour. The product was
 collected by filtration and washed with ethyl acetate to
 give 2197 g (83%) of the sodium 6,6-dibromo-

5 penicillanate sulfone. M.P. 186-187 °C. ¹HNMR (D₂O) δ 1.30 (s, 3H), 1.45 (s, 3H), 4.29 (s, 1H), 5.54 (s, 1H).

Step 2 - Preparation of benzyl 6,6-dibromopenicillanate sulfone


10



Dimethylformamide (5.7 L) and the sodium 6,6-dibromopenicillanate sulfone (3820 g) were combined and the mixture was stirred for a few minutes until all of the solids dissolved. To this mixture benzyl bromide (1400 g) was added over a 1 hour period. The reaction mixture was then stirred overnight at ambient temperature. Water (4.5 L) and ethyl acetate (15.0 L) were added to quench the reaction. The aqueous phase was washed with ethyl acetate (2 x 600 mL) and the combined organic phases were washed sequentially with a saturated aqueous sodium bicarbonate solution (2 x 1 L) and an aqueous sodium chloride solution (2 x 1 L). The organic layer was dried over magnesium sulfate and concentrated to give 3566 g (90%) of the desired benzyl 6,6-dibromopenicillanate sulfone as crystals. M.P. 146-147 °C. ¹HNMR (CDCl₃) δ 1.2 (s, 3H), 1.5 (s, 3H), 4.5 (s, 1H), 4.9 (s, 1H), 5.16 (d, 1H, J = 12 Hz), 5.29 (d, 1H, J = 12 Hz), 7.35-7.40 (m, 5H).

15
20
25
30

5 Step 3 - Preparation of benzyl 6- β -hydroxymethyl-6- α -
 bromopenicillanate sulfone



10 In a round bottom flask, paraformaldehyde was
heated under a nitrogen sweep to 160-180 °C to express
excess water. In a separate round bottom flask
tetrahydrofuran (8.0 L) and benzyl 6,6-
dibromopenicillanate sulfone (1000 g) were combined and
15 stirred until all of the solids had dissolved. The
solution was cooled to -78 °C and 3M methylmagnesium
chloride in THF (720 mL) was added slowly to the
solution while maintaining the temperature less than -70
°C. The reaction mixture was stirred for 1 hour. At
20 this time, formaldehyde gas expressed from the first
round bottom flask was blown over the surface of the
chilled reaction mixture using a stream of nitrogen.
This formaldehyde gas was expressed over the reaction
mixture for approximately 6 hours while maintaining
25 cooling and vigorous stirring of the chill reaction
flask. Upon reaction completion determined by TLC
(80:20 hexanes:ethyl acetate), the reaction was quenched
at -78 °C with a solution of acetic acid (132 mL) in THF
(400 ML). The reaction mixture was allowed to warm to
30 ambient temperature then the reaction mixture was
filtered through Supercel. The filtrate was

5 concentrated to an oil (~1000 g). The oil was then transferred to a large reaction vessel and ethyl acetate (5.0 L)/water (2.5 L) added. The mixture was stirred, then separated. The aqueous layer was washed with ethyl acetate (2 x 500 mL). The combined organic layers were
10 sequentially washed with 1N hydrochloric acid (3.0 L), water (3 x 3.0 L), and saturated aqueous sodium chloride solution (3 x 3.0 L). The organic layer was dried with magnesium sulfate, filtered through Supercel, concentrated and stored in a refrigerator. The
15 resulting oil was chromatographed through silica gel (1 Kg per 500 g of product oil), and eluted with 9:1 hexane/ ethyl acetate (20.0 L) to remove impurities then 4:1 hexane/ ethyl acetate (4.0-8.0 L) and finally 3:2 hexane/ ethyl acetate (as needed) until the benzyl 6- β -
20 hydroxymethyl-6- α -bromo-penicillanate sulfone was removed. Yield 205.5 g (23 %). M.P. 120-121 °C. (CDCl₃) ¹HNMR δ 1.28 (s, 3H), 1.57 (s, 3H), 4.09 (d, 1H, J = 16Hz), 4.54 (s, 1H), 4.62 (d, 1H, J = 16Hz), 4.82 (s, 1H), 5.18 (d, 1H, J = 16 Hz), 5.32 (d, 1H, J = 16
25 Hz), 7.36-7.42 (m, 5H).

Step 4 - Preparation of 4-Thia-1-azabicyclo
[3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-
dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R)

30 Water (163 mL), ethyl acetate (2000 mL), benzyl 6- β -hydroxymethyl-6- α -bromopenicillanate sulfone (180 g), triethylamine (90.0 g) and 5% palladium on carbon (45 g) were combined and hydrogenated at 50 psi at ambient temperature for approximately 2 hours. A TLC of the
35 reaction mixture showed the reaction was not complete so

5 additional catalyst (15 g) was added and the mixture was hydrogenated for one hour. Once the reaction was complete, the reaction was quenched with a mixture of sulfuric acid (112.5 g) and water (270 mL). The reaction mixture was filtered to remove catalyst, and
110 washed with EtOAc (450 mL). The aqueous layer was washed with EtOAc (3 x 750 mL). The organic phases were combined and dried with calcium chloride to a water content of less than 1%. The calcium chloride was then filtered out and the ethyl acetate was reduced to ½ its
15 volume. Fresh ethyl acetate was then back added to the solution and the water content of the solution was now 0.09%. Sodium ethyl hexanoate (59 g) and EtOAc (450 mL) were combined and added slowly to organic phase at ambient temperature. The mixture was then allowed to
20 granulate for a period of 30 to 45 minutes. The resulting solids were filtered, washed with EtOAc (500 mL) and dried to give 79.0 g (66%) of sodium 6-β-hydroxymethylpenicillanate sulfone. The solids were further purified via a recrystallized from 2-
25 propanol/water. M.P. 246-245 °C. ¹HNMR (D₂O) δ 1.23 (s, 3H), 1.39 (s, 3H), 3.82-3.89 (m, 1H), 3.97-4.10 (m, 3H), 4.85 (s, 1H).

Alternate Step 4 - Preparation of 4-Thia-1-azabicyclo
30 [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-
dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R)

Benzyl 6-β-hydroxymethyl-6-α-bromopenicillanate sulfone (1143 g) was placed in a large reaction vessel. Benzene (6.2 L) and tributyltin hydride (770 mL) were
35 added and the reaction mixture heated to reflux

5 temperature for 2-3 hours. The reaction was monitored by TLC, solvent = 1:1 hexane/ Ethyl acetate.

Upon reaction completion the mixture was concentrated to an oil to remove the benzene. The oil was washed with hexane at ambient temperature, until all the residual tin byproducts were removed. The material was reheated to reflux; ethyl acetate (EtOAc) was added to transfer material to single necked flask and concentrated. The material was washed with hexane (3 x) and the product layer dried under reduced pressure.

15 Half of the oil (549 g) was chromatographed over silica gel (1 Kg), with enough methylene chloride to get oil into solution, eluting with 7:3 hexane/EtOAc going to 3:2 hexane/EtOAc. The product fractions were combined and concentrated.


20 The oil (~540 g) was placed in an autoclave. Tetrahydrofuran (1.9 L), 10% palladium on carbon and water (300 mL) were added, and the reaction mixture hydrogenated at 50 psi, at a temperature of 30 °C, for approximately 1 hour. Upon reaction completion the reaction mixture was filtered through celite, to remove catalyst.

The filtrate was concentrated and diluted with EtOAc (3.0 L). The aqueous layer was washed with EtOAc (1.0 L). The combined organic layers were dried with calcium chloride, and concentrated to half volume. EtOAc (2.5 L) was added followed dropwise by a solution of sodium ethyl hexanoate (SEH, 250 g) and EtOAc (1.05 L). The resulting solids were removed by filtration and dried in a vacuum oven.

5 To the resulting solids, water (6-800 mL) was added and the pH adjusted to between 0.5 and 1.0 with 4M sulfuric acid. The product was extracted with EtOAc (5 x 1.0 L). The combined organic phases were dried with calcium chloride and filtered through a sparkle filter. 110 The filtrate was reduced to half volume and a solution of SEH (115.3 g) and EtOAc (500 mL) added. The mixture was allowed to granulate. The resulting solids were filtered and washed with EtOAc to give desired product.

Example 3

15 Prodrug 1: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (benzoyloxy)methyl ester, 4,4-dioxide (2S,5R,6R)



20


Prodrug 1, shown above, was prepared as follows.

To a stirred solution of 3.13 g (18.4 mmol.) chloromethyl benzoate (Narchem) in 200 mL acetone was added 13.8 g (92.1 mmol.) sodium iodide (Aldrich). The 25 resulting mixture was stirred at room temperature overnight. To this solution was added 3.5 g (12.3 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide, monosodium salt, (2S,5R,6R). The reaction mixture was 30 stirred overnight at room temperature. The reaction mixture was then concentrated in vacuo. Subsequently,

5 200 mL water and 200 mL ethyl acetate were added and the organic layer was separated and washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1:1 ethyl acetate/ hexanes afforded 8.62 g of an oil. The oil was then recrystallized from ethyl acetate/hexanes yielding 10 5.5 g of crystalline solid. The mother liquor still contained desired compound. Melting point = 102 °C. ¹H-NMR (DMSO): 7.97 (d, 2H, J=7.5Hz), 7.70 (t, 1H, J=7.5Hz), 7.56 (t, 2H, J=7.5Hz), 6.12 (d, 1H, J=6Hz), 15 5.99 (d, 1H, J=6Hz), 5.19 (d, 1H, J=5Hz), 5.17 (m, OH), 4.62 (s, 1H), 4.20 (m, 1H), 4.03 (m, 1H), 3.73 (m, 1H), 1.41 (s, 3H), 1.28 (s, 3H).

Example 4

20 Prodrug 2: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)




25 Prodrug 2, shown above, was prepared as follows.

To a stirred solution of 2.5 g (8.77 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxy-methyl)-3,3-dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R) in 20 mL DMF was added 2.1 g 30 (11.4 mmol.) (+/-)-benzoic acid 1-chloro-ethyl ester.

5 The resulting mixture was then heated to 35 °C for 3 days. 40 mL water and 100 mL ethyl acetate were added and the layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na₂SO₄,
10 filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1 L of 20 % ethyl acetate/ 80 % hexanes followed by 1 L 1:1 ethyl acetate/ hexanes afforded 1.2 g of an oil that was recrystallized using ethyl acetate/ hexanes affording 1 g of white
15 crystalline solid (mixture of 2 diastereomers). Melting point = 133-135°C. ¹H-NMR (d-DMSO, 400MHz): 7.96 (d, 2H, J=7.5Hz), 7.71 (t, 1H, J=7.5Hz), 7.55 (t, 2H, J=7.5Hz), 7.07 (q, 0.5H, J=5.4Hz), 7.03 (q, 0.5H, J=5.4Hz), 5.19 (d, 1H, J=5Hz), 5.15 (m, OH), 4.54 (s, 0.5H), 4.53 (s, 0.5H), 4.19 (m, 1H), 4.01 (m, 1H), 3.73 (m, 1H), 1.62 (d, 1.5H, J=5.4Hz), 1.61 (d, 1.5H, J=5.4Hz), 1.44 (s, 1.5H) 1.38 (m, 4.5H).

Example 5

25 Prodrug 3: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)




5 Prodrug 3, shown above, was prepared by the method of Example 4 by substituting (S)-Benzoic acid 1-chloro-ethyl ester and only heating to 30 °C. Melting Point = 154 °C. ¹H NMR (d-DMSO, 400 MHz): 7.96 (d, J= 7.5 Hz, 2H), 7.71 (t, J= 7.5 Hz, 1H), 7.55 (t, J= 7.5 Hz, 2H), 10 7.03 (q, J= 5.4 Hz, 1H), 5.19 (d, J= 5 Hz, 1H), 5.15 (m, OH), 4.53 (s, 1H), 4.18 (m, 1H), 4.02 (m, 1H), 3.72 (m, 1H), 1.61 (d, J= 5.4Hz, 3H), 1.39 (s, 3H), 1.37 (s, 3H). [α]_D = +119 (c = 0.0121, CHCl₃)

Prodrug 3 was also prepared by the following
15 alternative route. 52.03 g (182.4 mmol.) of 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,4,4-dioxide, monosodium salt, (2S,5R,6R), 61.50 g (181.1 mmol.) of tetrabutylammonium hydrogen sulfate, and 15.44 g (183.2
20 mmol.) of sodium hydrogen carbonate were combined at 20 °C. To this was added 400 mL dichloromethane while maintaining a temperature of 20 °C. Next 100 mL of water was added. The resulting mixture was stirred at 20 °C for 30 minutes. Organic layer was separated and dried
25 over sodium sulfate, filter and concentrated in vacuo. To the resulting residue was added 169.4 g (917.6 mmol.) (S)-Benzoic acid 1-chloro-ethyl ester followed by 160 mL acetone. The resulting solution was then stirred for 3 days at room temperature. Reaction was concentrated in
30 vacuo and chromatographed on silica gel using 40-50 % ethyl acetate/ hexanes as eluent. The resulting product was crystallized from ethanol followed by recrystallization from ethyl acetate/ hexanes.

5 Filtration and drying in vacuo yielded 85.9 g of white crystalline product.

Example 6

110 Prodrug 4: 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)




Prodrug 4, shown above, was prepared by the method
 15 of Example 4 by substituting (R)-benzoic acid 1-chloro-ethyl ester and only heating to 30 °C. ¹H-NMR (d-DMSO, 400MHz): 7.96 (d, 2H, J=7.5Hz), 7.71 (t, 1H, J=7.5Hz), 7.55 (t, 2H, J=7.5Hz), 7.07 (q, 1H, J=5.4Hz), 5.19 (d, 1H, J=5Hz), 5.15 (m, OH), 4.54 (s, 1H), 4.18 (m, 1H),
 20 4.01 (m, 1H), 3.72 (m, 1H), 1.62 (d, 3H, J=5.4Hz), 1.44 (s, 3H) 1.35 (s, 3H). MS (m/z): 410 (M⁻ -1, 100).

Example 7

25 Preparation of Carbonic Acids For Synthesizing
Comparison Prodrugs of 4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide
(2S,5R,6R)


32



5

Carbonic acid chloromethyl ester isopropyl ester, shown above, was prepared as follows. To a stirred solution of 10 grams (75.2 mmol.) chloromethyl chloroformate (Fluka) in 100 mL dichloromethane at 0 °C was added 5.8 mL (76 mmol.) isopropyl alcohol followed by 11.93 g (97.8 mmol.) dimethyl amino pyridine (Fluka). The resulting reaction mixture was then allowed to warm to room temperature and stir overnight. The reaction mixture is then diluted with water. The layers were then separated. The organic layer was washed with brine, dried over MgSO_4 filtered and concentrated in vacuo yielding 6 grams of a clear oil. The oil was then carried forwarded as is. $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): 5.72 (s, 2H), 4.95 (m, 1H, $J=6.2\text{Hz}$), 1.33 (d, 6H, $J=6.2\text{Hz}$).
Note: Better yields are achieved when only 1.05 equivalents of dimethyl amino pyridine are used.

20




25

(+/-)-Carbonic acid 1-chloro-ethyl ester isopropyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting chloroethyl chloroformate (Fluka). $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): 6.41 (q, 1H, $J=5.8$), 4.94 (m, 1H, $J=6.2\text{Hz}$), 1.81 (d, 3H, $J=5.8$), 1.32 (m, 6H).

30


33

5




(+/-)-Carbonic acid 1-chloro-ethyl ester propyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting propanol (Aldrich). ¹H-NMR (CDCl₃, 400 MHz): 6.41 (q, 1H, J=5.8), 4.17 (m, 2H), 1.81 (d, 3H, J=5.8), 1.71 (m, 2H), 0.96 (m, 3H).

15




(+/-)-Carbonic acid butyl ester 1-chloro-ethyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting n-butanol (Aldrich). ¹H-NMR (CDCl₃, 400 MHz): 6.41 (q, 1H, J=5.8), 4.20 (m, 2H), 1.81 (d, 3H, J=5.8), 1.67 (m, 2H), 1.41 (m, 2H), 0.93 (m, 3H).



Carbonic acid chloromethyl ester propyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting propanol (Aldrich). ¹H-NMR (CDCl₃, 400 MHz): 5.72 (s, 2H), 4.18 (t, 2H, J=6.6Hz), 1.71 (m, 2H), 0.97 (t, 3H, J=7.5Hz).


30



5


Carbonic acid butyl ester chloromethyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting n-butanol (Aldrich). ¹H-NMR (CDCl₃, 400 MHz): 5.72 (s, 2H), 4.23 (t, 2H, J= 6.6Hz), 1.70 (m, 2H), 1.41 (m, 2H), 0.94 (t, 3H, J=7.5Hz).

10




(+/-)-5-Bromo-5H-furan-2-one was prepared analogous to Tett. Lett. 22, 34, 1981, 3269-3272.

15



20

Acetic acid-1-chloro-1-methyl ethyl ester was Prepared as in Neuenschwander et al., *Helvetica Chimica* 1978; 61: 2047-2058.



25

Carbonic acid chloromethyl ester ethyl ester was prepared analogous to carbonic acid chloromethyl ester isopropyl ester by substituting ethanol. ¹H-NMR (CDCl₃,


5 400 MHz): 5.72 (s, 2H), 4.28 (q, 2H, J= 7.1Hz), 1.34 (t, 3H, J=7.1Hz).

Example 8

Preparation of Comparison Prodrugs of

110 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide
(2S,5R,6R)

Prodrugs of 4-thia-1-azabicyclo[3.2.0]heptane-2-
15 carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,
4,4-dioxide (2S,5R,6R) were prepared to demonstrate the
unexpectedly improved bioavailability, and physical
properties, of the prodrugs of the present invention.
Of these Comparison Prodrugs, Comparison Prodrug 1 is
20 described in Example 25 of U.S. Patent No. 4,287,181.
Comparison Prodrugs 2-15 are novel compounds but fall
within the scope of the genus disclosed in U.S. Patent
No. 4,287,181.

5 Comparison Prodrug 1:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy) methyl ester, 4,4-dioxide (2S,5R,6R)


To a stirred solution of 2.5 g (8.77 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide, monosodium salt, (2S,5R,6R) in 20 mL DMF was added (11.4 mmol.) chloromethyl pivalate (Aldrich) and stirred at room temperature overnight. The resulting mixture was then heated to 35 °C for 3 days. 40 mL water and 100 mL ethyl acetate were added and the layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1 L of 20 % ethyl acetate/ 80 % hexanes followed by 1 L 1:1 ethyl acetate/ hexanes yielded an oil. Hexanes (15 mL) were added to the oil and the sample was placed in the refrigerator for 4 days at which point a solid precipitated. It was then concentrated in vacuo yielding 110 mg of white amorphous solid. Melting point

37

5 = 70-73 °C. ¹H-NMR (CDCl₃, 400 MHz): 5.94 (d, 1H, J=5.4Hz), 5.70 (d, 1H, J=5.4Hz), 4.69 (d, 1H, J=4.1Hz), 4.48 (s, 1H), 4.30 (m, 1H), 4.15 (m, 2H), 1.55 (s, 3H), 1.41 (s, 3H), 1.21 (s, 9H).

Alternately, this compound, which is also known as
 10 pivaloyloxymethyl 6-β-hydroxymethylpenicillinate sulfone, can be prepared as described in Example 25 of U.S. Patent No. 4,287,181.

Comparison Prodrug 2:




15
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(ethoxycarbonyl)oxy] methyl ester, 4,4-dioxide
(2S,5R,6R)

20 This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that carbonic acid chloromethyl ester ethyl ester was substituted for chloromethyl pivalate. Melting point
 25 (amorphous solid) = 103-105 °C. ¹H-NMR (MeOD, 400 MHz): 5.91 (d, 1H, J=5.8Hz), 5.76 (d, 1H, J=5.8Hz), 4.96 (d,

5 1H, J=4.6Hz), 4.55 (s, 1H), 4.15-4.25 (m, 4H), 3.95 (m, 1H), 1.53 (s, 3H), 1.41 (s, 3H), 1.29 (t, 3H, J=7.1).

Comparison Prodrug 3:




10

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1,3-dihydro-3-oxo-1-isobenzofuranyl ester, 4,4-dioxide (2S,5R,6R)

15 This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that 3-bromo phthalide (Aldrich) was substituted for chloromethyl pivalate.

Upon dilution of DMF with water the desired product
 20 precipitated as an amorphous solid and was filtered and dried *in vacuo*. MS (m/z): 394 (M⁻) NMR represents a mixture of diastereomers. ¹H-NMR (d-DMSO, 400 MHz):
 7.8-8.0 (m, 4H), 7.60 (s, 0.5H), 7.59 (s, 0.5H), 5.23 (m, 1H), 5.16 (OH), 4.71 (s, 0.5H), 4.67 (s, 0.5H), 4.20 (m, 1H), 4.02 (m, 1H), 3.74 (m, 1H), 1.47 (s, 1.5H),
 25 1.37 (s, 1.5H), 1.36 (s, 1.5H), 1.31 (s, 1.5H).


5 Comparison Prodrug 4:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, [(1-methylethoxy)carbonyl]oxy] methyl ester, 4,4-dioxide (2S,5R,6R)

To a stirred solution of (18.4 mmol.) carbonic acid chloromethyl ester isopropyl ester in 200 mL acetone was added 13.8 g (92.1 mmol.) sodium iodide (Aldrich). The resulting mixture was stirred at room temperature overnight. To this solution was added 3.5 g (12.3 mmol.) 4-thia-1-azabicyclo [3,2,0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 4,4-dioxide, monosodium salt, (2S,5R,6R) (US 4,287,181) and the reaction mixture was stirred overnight at room temperature. The reaction mixture was then concentrated in vacuo. 200 mL water and 200 mL ethyl acetate were added and the organic layer was separated and washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. Chromatography on silica gel eluting with 1:1 ethyl acetate/ hexanes. The final product was a reddish oil. MS (m/z): 378 (M⁻). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=5.8Hz), 5.74 (d, 1H, J=5.8Hz), 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.82 (m, 1H), 4.60 (s, 1H),

5 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.42 (s, 3H),
1.30 (s, 3H), 1.22 (d, 6H, J=6.2Hz).

Comparison Prodrug 5:




10

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-[[[(1-methylethoxy) carbonyl]oxy] ethyl ester, 4,4-dioxide (2S,5R,6R)


15 This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid 1-chloro-ethyl ester isopropyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z): 392 (M⁻). NMR is of a reddish
20 oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.71 (q, 0.5H, J=5.4Hz), 6.67 (q, 0.5H, J=5.4Hz), 5.20 (d, 1H, J=5Hz), 4.79 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.48 (m, 3H), 1.43 (s, 1.5H), 1.39 (s, 1.5H),
25 1.33 (m, 3H), 1.22 (m, 6H).

41

5 Comparison Prodrug 6:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-
[(propoxycarbonyl)oxy]ethyl ester, 4,4-dioxide
(2S,5R,6R)


This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid 1-chloro-ethyl ester propyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z): 392 (M⁻). NMR is of a yellow-reddish oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.72 (q, 0.5H, J=5.4Hz), 6.68 (q, 0.5H, J=5.4Hz), 5.20 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 3H), 3.74 (m, 1H), 1.59 (m, 2H), 1.48 (m, 3H), 1.39 (s, 1.5H), 1.34 (s, 1.5H), 1.22 (m, 3H), 0.86 (m, 3H).

5 Comparison Prodrug 7:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-
[(butoxycarbonyl)oxy]ethyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid butyl ester 1-chloro-ethyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. MS (m/z): 406 (M⁻). NMR is of a yellow-reddish oil that is a mixture of 2 diastereomers ¹H-NMR (d-DMSO, 400 MHz): 6.72 (q, 0.5H, J=5.4Hz), 6.68 (q, 0.5H, J=5.4Hz), 5.20 (m, 1H), 4.51 (s, 0.5H), 4.49 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 3H), 3.74 (m, 1H), 1.59 (m, 2H), 1.15-1.55 (m, 11H), 0.86 (m, 3H).


43

5 Comparison Prodrug 8:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(propoxycarbonyl)oxy]methyl ester, 4,4-dioxide
(2S,5R,6R)


This prodrug was prepared according to the method used to p:
 isopropyl ester. The final product was an amorphous
 white solid. MS (m/z): 378 (M⁻). ¹H-NMR (d-DMSO, 400
 15 MHz): 5.86 (d, 1H, J=6.2Hz), 5.74 (d, 1H, J=6.2Hz),
 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.60 (s, 1H), 4.20
 (m, 1H), 4.10 (m, 2H), 4.03 (m, 1H), 3.74 (m, 1H), 1.60
 (m, 2H), 1.42 (s, 3H), 1.30 (s, 3H), 0.86 (t, 3H,
 J=7.5Hz).

20

5 Comparison Prodrug 9:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-
, [(butoxycarbonyl)oxy]methyl ester, 4,4-dioxide
(2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that carbonic acid butyl ester chloromethyl ester was substituted for carbonic acid chloromethyl ester isopropyl ester. The final product was an amorphous white solid. MS (m/z): 392 (M⁻). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=6.2Hz), 5.74 (d, 1H, J=6.2Hz), 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.60 (s, 1H), 4.20 (m, 1H), 4.15 (m, 2H), 4.03 (m, 1H), 3.74 (m, 1H), 1.60 (m, 2H), 1.42 (s, 3H), 1.30 (m, 2H), 1.30 (s, 3H), 0.86 (t, 3H, J=7.5Hz) ..

5 Comparison Prodrug 10:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, 2,5-dihydro-5-oxo-2-
furanyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that 5-bromo-5H-furan-2-one was substituted for
15 chloromethyl pivalate. MS (m/z): 344 (M⁻). NMR is a mixture of 2 diastereomers. The product was an amorphous solid. ¹H-NMR (d-DMSO, 400 MHz): 7.81 (m, 0.5H), 7.73 (m, 0.5H), 7.14 (m, 0.5H), 7.10 (m, 0.5H), 6.61 (m, 1H), 5.21 (m, 1H), 5.17 (m, OH), 4.67 (s,
20 0.5H), 4.63 (s, 0.5H), 4.20 (m, 1H), 4.03 (m, 1H), 3.74 (m, 1H), 1.42 (s, 1.5H), 1.40 (s, 3H), 1.32 (s, 1.5H).

5 Comparison Prodrug 11:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1-oxobutoxy) methyl
ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 4 with the exception that chloromethyl butyrate (Acros organics) was substituted for chloromethyl pivalate. The product was a clear oil. MS (m/z): 362 (M⁺). ¹H-NMR (d-DMSO, 400 MHz): 5.86 (d, 1H, J=5.8Hz), 5.74 (d, 1H, J=5.8Hz), 5.20 (d, 1H, J=5Hz), 5.17 (m, OH), 4.55 (s, 1H), 4.20 (m, 1H), 4.01 (m, 1H), 3.74 (m, 1H), 2.35 (m, 2H), 1.52 (m, 2H), 1.40 (s, 3H), 1.30 (s, 3H), 0.86 (m, 3H).

5 Comparison Prodrug 12:


10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-(hydroxymethyl)-3,3-dimethyl-7-oxo-,1,3-dihydro-3-oxo-1-isobenzofuranyl ester, 4,4-dioxide (2S,5R,6R)

Prepared by chromatography on silica gel of 275 mg of Comparison Prodrug 3 using 5% isopropyl alcohol/ 95% methylene chloride yielded 200mg of a mixture of
 15 diastereomers followed by 70 mg of a single, (more polar) diastereomer. The product was an amorphous solid. MS (m/z):394 (M⁻) NMR represents the more polar diastereomer. ¹H-NMR (d-DMSO, 400 MHz): 7.95 (d, 1H, J=7.5Hz), 7.90 (m, 1H), 7.81 (d, 1H, J=7.5Hz), 7.77 (m,
 20 1H), 7.60 (s, 1H), 5.23 (d, 1H, J=5Hz), 5.16 (OH), 4.71 (s, 1H), 4.20 (m, 1H), 4.02 (m, 1H), 3.74 (m, 1H), 1.47 (s, 3H), 1.37 (s, 3H).

5 Comparison Prodrug 13:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, .6-
(hydroxymethyl)-3,3-dimethyl-7-oxo-, (acetyloxy) methyl
ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that bromomethyl acetate (Aldrich) was substituted for
15 chloromethyl pivalate. The final product was a viscous oil. MS (m/z): 334 (M⁻). ¹H-NMR (d-DMSO, 400 MHz):
5.82 (d, 1H, J=6.2Hz), 5.72 (d, 1H, J=6.2Hz), 5.19 (d, 1H, J=5Hz), 5.17 (m, OH), 4.55 (s, 1H), 4.20 (m, 1H),
4.01 (m, 1H), 3.74 (m, 1H), 2.08 (s, 3H), 1.40 (s, 3H),
20 1.30 (s, 3H).

5 Comparison Prodrug 14:

10 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, 1-(acetyloxy)-1-methylethyl ester, 4,4-dioxide (2S,5R,6R)

This prodrug was prepared according to the method used to prepare Comparison Prodrug 1 with the exception that acetic acid-1-chloro-1-methyl ethyl ester was substituted for chloromethyl pivalate. The final product was an amorphous solid. MS (m/z): 362 (M⁻). ¹H-NMR (CDCl₃, 400 MHz): 4.68 (d, 1H, J=5.0Hz), 4.40 (s, 1H), 4.31 (m, 1H), 4.15 (m, 2H), 2.06 (s, 3H), 1.92 (s, 3H), 1.82 (s, 3H), 1.58 (s, 3H), 1.47 (s, 3H).

20

Example 9Chemical (pH), Suspension and Plasma Stability

The stability of Prodrug 3 was evaluated with regards to (1) chemical stability while in solutions of various pH, (2) maintaining potency while in suspension, and (3) chemical stability in plasmas from various mammals to assess the ability of Prodrug 3 to resist hydrolysis

25

5 prior to absorption and then to rapidly hydrolyze to form 6- β -HMPAS after absorption.

Chemical stability of Prodrug 3, in solution, as compared to the sodium salt of 6- β -HMPAS (hereinafter "Na HPMAS") and lithium clavulanate in solution, was
10 assessed at pH 1, 2, 2.5, 4.0, 5.0, 6.5, and 7.4. Buffers were appropriately formulated to achieve the desired pH of each incubation. The incubation consisted of 990 μ l of the appropriate pH buffer and was initiated with the addition of 10 μ l of a 10 mM stock of compound
15 in 100% methanol (final concentration = 100 μ M). Serial samples (20 μ l) were taken at 0, 10, 20, 40, 60, 120, and 240 minutes by an auto injector and injected directly onto an HPLC in-line with a LC/MS single quadropole mass spectrometer system used for analyte
20 detection. The temperature of the incubation was regulated with a 96-well heat block. Incubations were performed at 25°C and 37°C. The LC/MS system was run in the negative ion mode. Selective ion monitoring of the appropriate $[M-H]^-$ for each analyte was used for
25 detection and quantitation of remaining compound at each timepoint. The peak response at each time point was expressed as a percentage of that obtained at time = 0. A degradation rate constant (k_d) was obtained by regression of these percentages from time = 0 minutes to
30 time = 240 minutes. An apparent first-order half-life could then be estimated as $\ln 2/k_d$. These determinations were completed in duplicate and the average was reported.

5 As shown in the following table, Prodrug 3 demonstrated excellent acid stability and adequate stability near neutral pH for absorption. Also, Na-HMPAS demonstrated superior solution stability compared to clavulanate, particularly at low pH.

10 The stability of Prodrug 3 in suspension (unbuffered in 0.5% methylcellulose at 25 °C) was also evaluated to determine the effect of time in suspension upon potency. As shown below, Prodrug 3 maintained greater than 90% of its potency after storage at room
15 temperature for 10 days. By contrast, only 40% of potency is retained with clavulanate in the Augmentin suspension if left at room temperature for the same time period (See Mehta, A.C., S. Hart-Davies, J. Payne and R.W. Lacey, 1994. Stability of amoxicillin and
20 potassium clavulanate in a co-amoxicillin-clavulanate oral suspension. *J. Clin. Pharm. Ther.* 19:313-315.)).

5

	pH					
Solution Stability (100 µM)	7.4	6.5	5.0	4.0	2.5	1.2
	Half-life (Hours)					
Prodrug 3 (25 °C)	2.7	>24	>24	>24	>24	>24
Prodrug 3 (37 °C)	0.6	4.5	>24	>24	>24	>24
Na-HMPAS (25 °C)	>24	>24	>24	>24	>24	>24
Na-HMPAS (37 °C)	>24	>24	>24	>24	>24	>24
Clavulanate (25 °C)	>24	>24	>24	>24	1.2	0.6
Clavulanate (37 °C)	>24	>24	>24	>24	0.9	ND
Prodrug 3 Suspension Stability	Day 1	Day 3	Day 5	Day 7	Day 10	
	Potency (percent) *					
1.51 mg/ml** (10 mg/kg rat dose preparation)	ND	103	98	104	91**	*

*Potency assessed as a percentage of the target concentration as assayed by LC/MS of solubilized standards. Values represent an average of duplicate determinations. ND = not determined

10

** pH of initial suspensions ~6.8 and fell to 4.7 by day 10

*** diastereomer mixture essentially unchanged ~ 95:5

15

Plasma stability of Prodrug 3, Na-HMPAS and lithium clavulanate were determined, in mouse, rat, dog, monkey

5 and human plasma, using plasma that was prepared and subjected to one freeze/thaw cycle prior to use. The incubation consisted of 990 μ l of plasma preincubated for 5 minutes at 37 °C in a 96-well heat block. The incubation was initiated with the addition of 10 μ l of a
10 10 mM stock of compound in 100% methanol. Serial aliquots (100 μ l) were removed and transferred to 200 μ l of 75/25 acetonitrile/3% perchloric acid at 0, 1, 2, 5, 10, 20, 30, and 60 minutes. The samples were centrifuged, the supernatants transferred to injection
15 vials, and 20 μ l was injected onto the HPLC in-line with a LC/MS single quadropole mass spectrometer. The LC/MS system was run in the negative ion mode. Selective ion monitoring of the appropriate $[M-H]^-$ for each analyte was used for detection and quantitation of remaining
20 compound at each timepoint. The peak response at each time point was expressed as a percentage of that obtained at time = 0. A degradation rate constant (k_d) was obtained by regression of these percentages from time = 0 minutes to time = 240 minutes. An apparent
25 first-order half-life was then be estimated as $\ln 2/k_d$. These determinations were completed in duplicate and the average was reported as shown below.

5

Plasma Stability (100 μ M)	Mouse	Rat	Dog	Monkey	Human
	Half-life				
Prodrug 3 37 °C	2.8 min	<2.0 min	2.8 min	3.6 min	<2.0 min
Na-HMPAS 37 °C	3.9 hr	3.4 hr	> 4 hr	>4 hr	>4 hr
Clavulanate 37 °C	>4 hr	3.3 hr	2.8 hr	3.6 hr	2.6 hr

Prodrug 3 demonstrated excellent acid stability and adequate stability near neutral pH for absorption. Hydrolysis rates of Prodrug 3 in the plasma of all species tested, demonstrate efficient enzymatic hydrolysis to yield 6- β -HMPAS upon absorption. Na-HMPAS demonstrated superior solution stability compared to clavulanate, particularly at low pH. Although both compounds are labile in plasma, Na-HMPAS shows improved human plasma stability.

Example 10

Inhibitory activity of Prodrug 3 at intestinal pH values

It is thought that clavulanate produces diarrhea in the human GI tract since it combines with residual amoxicillin to selectively kill essential components of the normal flora. Clavulanate is not a prodrug, and

5 thus the 40% that remains unabsorbed from the intestine
is the same active molecule as the 60% that is absorbed
into circulation. While the pH of the stomach and
proximal small intestine is acidic, in a study by Berry,
V. et al., *Efficacy of a pharmacokinetically enhanced*
110 *formulation of amoxicillin/clavulanate against*
experimental respiratory tract infection in rats caused
by Streptococcus pneumoniae, Abstract B988, 41st
Interscience Conference on Antimicrobial Agents and
Chemotherapy, December 16-19th, 2001 Chicago, IL., found
15 that the median pH of 24h stool samples collected from
subjects with diarrhea was 6.4 (range 5.4-7.8).

As shown in Example 7, Prodrug 3 is very stable and
does not readily convert to 6- β -HMPAS at pH < 6.5. In
order to compare the beta-lactamase inhibitory activity
20 of Prodrug 3 and Na-HMPAS under pH conditions found in
the human large intestine, we determined the IC₅₀ of both
compounds against a TEM-1 beta-lactamase at pH 6.0 and
7.0. The data indicate that at pH 6.0, where there
should be no conversion of the prodrug to the active
25 form of the inhibitor, Prodrug 3 is inactive against
TEM-1 beta-lactamase (IC₅₀ >100 μ M). In contrast, at pH
7.0 where conversion of the prodrug to active inhibitor
occurs with a half-life of 33 minutes, the resulting 6-
 β -HMPAS generated results in a much greater level of
30 inhibition of this beta-lactamase than was observed at
pH 6.0.

5

		IC ₅₀ (μM)	
		Prodrug 3	6-β-HMPAS
	E. coli TEM-1 pH 6.0	> 100	0.37
10	E. coli TEM-1 pH 7.0	2.2	0.12

Example 11

Absorption (Oral *In Vivo* Bioavailability)

As Prodrug 3 has a solution half-life of 30 minutes at neutral pH and, in the presence of esterases, the prodrug is hydrolyzed within a few minutes, an *in vitro* assessment using the human Caco-2 cell line was determined to be inappropriate to measure prodrug absorption. Instead, an *in vivo* model for absorption was found to be more relevant for assessing absorption of the prodrugs of the present invention. Further, the correlation of fraction absorbed in the rat to that of human has been studied in several marketed agents and the correlation has been shown to be quite good (corr = 0.971) (See Chiou, W.L. and A. Barve, 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. *Pharm. Res.* 15:1792-1795.). Based upon this correlation, the rat was used to predict human absorption. It should be further appreciated that 6-β-HMPAS demonstrated minimal hepatic extraction as suggested by rat and human hepatocytes. Thus, oral bioavailability assessments in rats should correlate well with the fraction absorbed in humans.

Estimates of oral bioavailability were conducted on

5 Na-HMPAS, Prodrugs 1, 2, 3 and 4, as well as the
fourteen comparison prodrugs of Example 8, each using
sets of three Sprague-Dawley rats (200-225 gm) equipped
with surgically implanted jugular vein catheters. The
selection of dose vehicles, for the oral studies,
110 depended upon the physical state of the compound being
tested. All compounds that were orally administered,
with the exception of Prodrug 1, were in the form of an
oil or an amorphous solid. As such, these compounds
were administered in a solution (PO) dosage form using a
15 70/20/10 water/Chremophore/ethanol vehicle.

The oral prodrug doses were prepared to deliver a
10 mg/kg equivalent dose of 6- β -HMPAS at a dose volume
of 10 ml/kg. Na-HMPAS was administered intravenously
at a dose of 10 mg/kg to establish bioavailability
20 estimates (6- β -HMPAS equivalent).

Blood samples were taken at 0, 15, 30 min., 1, 2,
3, and 5 hr. after dosing. The samples were then
processed for plasma and stored at -20 °C prior to
analysis. Samples were assayed for 6- β -HMPAS, as
25 described below, and then the mean concentration versus
time profiles for oral and intravenous administration
were determined. The area under the plasma
concentration versus time curve ($AUC_{0-t_{last}}$) was
calculated from time 0 to the last quantifiable
30 timepoint using linear trapezoidal approximation. The
terminal elimination rate constant (K_{el}) was estimated by
regression of the plasma concentration data from the
apparent beginning of the elimination phase to the last
sample point. An elimination half-life was estimated as
35 $\ln 2/K_{el}$. The area from t_{last} to infinity ($AUC_{t_{last}-\infty}$)

5 was estimated at $C_{est_{t_{last}}}/K_{el}$ where $C_{est_{t_{last}}}$ represents the estimated concentration at the last time point in which drug was quantified based on the regression analysis. The total area under the curve ($AUC_{0-\infty}$) was estimated as the sum of $AUC_{0-t_{last}}$ and $AUC_{t_{last}-\infty}$. Bioavailability (F) was expressed as $AUC_{(0-\infty)_{po}} \times Dose_{iv} / AUC_{(0-\infty)_{iv}} \times Dose_{po}$.

The mean bioavailabilities found were as shown below.

5

Compound	Mean Bioavailability	Standard Deviation
Na-HMPAS	6.0	1.6
Prodrug 1	113.1	10.7
Prodrug 2	102.0	11.1
Prodrug 3	92.4	6.0
Prodrug 4	111.1	8.8
Comparison Prodrug 1	55.4	4.7
Comparison Prodrug 2	6.2	1.0
Comparison Prodrug 3	27.2	2.6
Comparison Prodrug 4	6.8	0.9
Comparison Prodrug 5	46.5	1.4
Comparison Prodrug 6	60.9	6.1
Comparison Prodrug 7	40.3	10.8
Comparison Prodrug 8	7.9	1.5
Comparison Prodrug 9	12.3	2.0
Comparison Prodrug 10	10.9	1.7
Comparison Prodrug 11	33.1	5.4
Comparison Prodrug 12	20.4	1.0
Comparison Prodrug 13	37.6	3.7
Comparison Prodrug 14	15.4	3.9

As shown above, the prodrugs of the present invention have significantly better bioavailabilities than does 6- β -HMPAS, the previously known Comparison

5 Prodrug 1, or the prior generically disclosed prodrugs
(Comparison Prodrugs 2-14).

Assay Description:

In this assay, the analytes of interest were back
10 extracted into the aqueous phase following acetonitrile
precipitation and treatment with chloroform. This
provided approximately a 2 fold concentration factor
without having an evaporation and reconstitution step.

Detection was afforded through the use of LC/MS/MS
15 in negative ion operation. Single quadrapole operation
was inadequate for selective detection of the analyte.

The pH of the loading solvent (95:5 20 mM ammonium
formate/acetonitrile; solvent A) was ~ 5.0.

The analytical column was an Phenomenex AQUA C18
20 4.6 x 50 mm.

All sample preparation was completed in 96-well 1.2
mL MARSH-tubes. The samples were prepared as follows.
The Plasma sample (200 µl) was added to 400 µl of 95:5
acetonitrile:20 mM ammonium formate containing 5 µg/ml
25 sulbactam as an internal standard. The samples were
centrifuged at 3000 rpm for 10 min in a table top
centrifuge. The supernatant (400 µl) was then
transferred to clean 1.2 ml MARSH[®] tubes. Chloroform
(600 µl) was added to the samples, which were then
30 mixed, and subsequently centrifuged at 3000 rpm for 10
minutes. The transferred aqueous phase was then removed
from top (~ 100 µl) and then analyzed.

Mass Spectrometry Conditions:

61

- 5 Mass Spectrometer: API-3000 operated in negative ion
mode using Turbo spray (electrospray)
Ionization voltage: -3000V
Orifice voltage: -25 eV
Collision energy: 30 eV
110 Nebulization and Heat gas adjusted as needed

Reaction Monitoring:

- 6- β -HMPAS: 262 => 218
Sulbactam (IS): 232 => 140
15 Amoxicillin: 364 => 223
Clavulanic acid: 198 => 136
Run time: 3 min.
RT: ~ 2 min for all analytes
Injection Volume: 20 μ l

20 HPLC Conditions:

Solvent A: 95:5 20 mM ammonium formate: acetonitrile
Solvent B: 95:5 acetonitrile: 20 mM ammonium formate
Analytical Flow: 1 ml/min
Flow to Mass Spectrometer: ~100 μ l/min

25 Ballistic Gradient Schedule:

- 0 - 0.5 min 100 % A
0.5- 1 min 100% A to 100% B
1-1.5 min 100% B
1.5 - 2.0 min 100% B to 100% A
30 LLOQ = 0.1 μ g/ml for 6- β -HMPAS and amoxicillin, 0.5
 μ g/ml clavulanic acid
ULOQ = 50 μ g/ml (All)
Regression = linear 1/x weighting
Column life ~ 300 - 400 injections

5 Portal Vein Studies in Rats: Systemic exposure of
Prodrug 3 was also assessed in portal vein cannulated
rats following oral administration of the prodrug at a
dose of 100 mg/kg. Whole blood aliquots were stabilized
in ice cold acid immediately upon sampling at 5, 15 and
10 30 minutes post dose. No levels of Prodrug 3 were
detected in any of the samples (assay LLOQ of 100
ng/ml). These results suggest that, upon absorption,
Prodrug 3 undergoes rapid hydrolysis to yield 6- β -HMPAS
prior to exposure to the liver and circulation
15 throughout the body.

Example 12

In Vitro Screens

Biochemical activity against β -lactamases from
20 community respiratory pathogens: Only three beta-
lactamase inhibitor molecules exist in the marketplace:
sulbactam, clavulanate and tazobactam. All three
inhibit type A penicillinases found in a broad range of
bacteria. Of these, only clavulanate is directed toward
25 oral therapy of community respiratory infections. Na-
HMPAS was tested against a collection of cell-free
penicillinases commonly found in *H. influenzae* and *M.*
catarrhalis that are resistant to ampicillin. The data
in the following table indicates that Na-HMPAS is
30 equivalent to lithium clavulanate against the ROB-1 and
TEM-1 enzymes from *H. influenzae*. All three beta-
lactamase inhibitors were very potent against the BRO-1
and BRO-2 penicillinases found in *M. catarrhalis*, with
sulbactam being the most active (Table 1). A broader
35 analysis of β -lactamases from 30 recent clinical

- 5 isolates of *M. catarrhalis* showed that Na-HMPAS was effective at inhibiting the BRO-1, and BRO-2 enzymes from all of these strains, with an average IC₅₀ of 0.19 μ M.

IC ₅₀ s of β -lactamase inhibitors against β -lactamases in cell extracts				
	β -lactamase	IC ₅₀ (μ M) *		
Strains	Type	Sulbactam	6- β -HMPAS	Clavulanate
<i>H. influenzae</i> ATCC43334	ROB-1	3.40	0.01	0.04
<i>H. influenzae</i> 54A1173	TEM-1	4.78	0.03	0.02
<i>M. catarrhalis</i> 87A1178 ATCC43617	BRO-2	0.03	0.32	0.11
<i>M. catarrhalis</i> 87A1115	BRO-1	0.011	0.143	0.14

*All inhibitory values are determined against the
10 chromogenic cephalosporin in a colorimetric assay.

Biochemical activity against β -lactamases from other pathogens, including those associated with skin infections: Na-HMPAS was comparable to clavulanate in
15 terms of its inhibitory potency against a wide variety of TEM extended spectrum beta-lactamases (ESBLs) while Na-HMPAS and clavulanate were usually comparable in potency against ESBLs.

Inhibition of selected extended spectrum β -lactamases (ESBLs) (IC_{50} , μM)				
Inhibitor				
	β -lactamase	IC_{50} (μM) *		
Strains	Type	Sulbactam	6- β -HMPAS	Clavulanate
<i>E. coli</i> ATCC35218	TEM-1	6.85	0.14	0.05
<i>E. coli</i> 51A1101	TEM-1	4.76	0.07	0.02
<i>K. pneumoniae</i> CF104	TEM-3	0.55	<0.003	<0.003
<i>K. pneumoniae</i> CF504	TEM-5	4.68	0.08	<0.003
<i>K. pneumoniae</i> B L-1	TEM-10	23.19	0.39	>100
<i>K. pneumoniae</i> MCV37	TEM-12	5.86	0.27	<0.003
<i>K. pneumoniae</i> CF1304	TEM-16	5.80	0.09	0.06
<i>K. pneumoniae</i> E264	TEM-17	10.36	0.66	0.004
<i>K. pneumoniae</i> CF1104	TEM-24	10.48	7.13	0.01
<i>E. coli</i> CF1609	TEM-25	2.58	0.04	0.02
<i>K. pneumoniae</i> 5657	TEM-26	0.56	0.08	0.02
<i>Serratia</i> S6	Sme-I	15.65	0.68	19.55

5 *All inhibitory values are determined against the chromogenic cephalosporin in a colorimetric assay.

In general, it can be concluded that Na-HMPAS is comparable to lithium clavulanate.

5

Susceptability assay for β -lactamase producing species
H. influenzae and *M. catarrhalis*: The *in vitro* activity
of various ratios of 6- β -HMPAS and amoxicillin was
assessed using clinical isolates of *H. influenzae* and *M.*
10 *catarrhalis* that produce β -lactamase. The NCCLS
(National Committee for Clinical Laboratory Standards)
approved susceptibility method for Augmentin uses a
fixed 2:1 ratio of amoxicillin/clavulanate. The results
indicated that for 46 beta-lactamase (+) strains of *H.*
15 *influenzae*, the amoxicillin MIC₅₀ and MIC₉₀ values (i.e.,
the minimal inhibitory concentrations required to
prevent the growth of either 50% or 90% of the isolates
tested) for both amoxicillin/clavulanate and
amoxicillin/6- β -HMPAS were 1 and 2 μ g/ml, respectively,
20 while the values for 2:1 amoxicillin/sulbactam were 4
and 8 μ g/ml. Note that the numbers refer to the
amoxicillin concentration in the mixture.

For 48 isolates of *M. catarrhalis*, the MIC₅₀ and
MIC₉₀ values for amoxicillin/clavulanate were ≤ 0.125 and
25 0.25 μ g/ml, and 0.5 and 1.0 μ g/ml for amoxicillin/6- β -
HMPAS, respectively. Values for amoxicillin/sulbactam
(2:1) were 0.25 and 1.0 μ g/ml. Thus, MICs obtained with
whole cells do not always correlate well with inhibitor
potencies against cell-free beta-lactamases, as
30 sulbactam was consistently more potent against the BRO-
1/2 enzymes found in *M. catarrhalis*.

Susceptability assay for Non- β -lactamase producing
species *Streptococcus pneumoniae*: The *in vitro* activity

5 of the combination was compared with that observed with amoxicillin alone against clinical isolates of *S. pneumoniae* that were classified as penicillin-susceptible, -intermediate and -resistant. Some of these strains showed high-level resistance to
10 penicillin and amoxicillin with MICs in the 4-8 µg/ml range. As expected for a pathogen with PBP-based resistance, results for isolates of *S. pneumoniae* confirmed that the presence of inhibitors had no influence on amoxicillin MICs.

15 The amoxicillin MIC₅₀s and MIC₉₀s for 21 penicillin-resistant strains (penicillin MICs from 1-8 µg/ml) were 2 and 4 µg/ml for amoxicillin alone and for all beta-lactamase inhibitor combinations tested at amoxicillin/inhibitor ratios of 2:1, 7:1 and 14:1.
20 Finally, all combinations were tested against a group of 21 penicillin-intermediate *S. pneumoniae* and 12 penicillin-susceptible isolates. Again, all of the MICs in both groups reflected the amoxicillin component of the combination. Amoxicillin MICs for the intermediate
25 group ranged from 0.03 to 1 µg/ml and the MICs for the susceptible group were ≤0.0156 to 0.06 µg/ml.

Assay Methodology: The assay was performed according to the method described in NCCLS Document M7-A4, December
30 1997 and M100-S12, 2002, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically- Approved Standard.

PREPARATION OF FROZEN STOCKS: *H. influenzae* are grown on chocolate agar plates. Colonies are suspended

5 into Haemophilus test medium (HTM, Remel Diagnostics)
which has been pH adjusted to 7.4, with 1N NaOH and
filter sterilized. This is mixed with 50% glycerol to a
final concentration of 20% glycerol. Growth of
Streptococcus pneumoniae and *Moraxella catarrhalis* is
10 scraped off sheep blood agar plates and placed into
Mueller Hinton broth plus 5% lysed sheep blood. For
freezing, 50% glycerol is added to a final concentration
of 20%. All are frozen at -70 °C.

PREPARATION OF DRUG PLATES: 96-well microtiter
15 plates are used for the drug dilutions. All drugs are
weighed out in sufficient quantity to make a 4X working
stock solution. Drug is solubilized in DMSO or other
appropriate solvent, dissolved to volume in testing
medium, and 100 µl is serially diluted twofold through a
20 series of 10 drug wells each containing an initial
volume of 100 µl medium [columns 1 through 10] and 1
drug well with no inoculum [column 11]. Column 12 is a
bacterial inoculum control well containing no drug.
Final volume in each well is 100 µl.

25 Drug plates for *H. influenzae* are serially diluted
in HTM which has been pH adjusted to 7.4 with 1 N NaOH
and filter sterilized. The other two species are
diluted in Mueller Hinton broth plus 5% lysed horse
blood. Control compounds are run with each assay. Drug
30 plates are frozen at -70 °C and thawed on the day of
use.

GROWTH OF INOCULUM: *H. influenzae* are grown
overnight on Mueller Hinton agar plates with 1%
hemoglobin and with 1% GCHI [chocolate agar plates] in a
35 5% CO₂ incubator overnight at 37 °C. *S. pneumoniae* and

5 *M. catarrhalis* are grown on Mueller Hinton agar containing 5% sheep blood under the same conditions.

PREPARATION OF INOCULUM: Overnight growth from an agar plate was taken and resuspended in the appropriate test medium. All suspensions were adjusted to a standard OD by spectrophotometry on the day of the assay using Haemophilus test medium (HTM) broth for *H. influenzae* or cation supplemented Mueller Hinton broth plus 5% lysed horse blood (for *S. pneumoniae* and *M. catarrhalis*) to a turbidity corresponding to a 0.5 McFarland standard suspension (about $1 \text{ to } 2 \times 10^8$ CFU/ml). This suspension had an OD₆₂₅ of 0.14. To obtain a final inoculum of $2\text{-}7 \times 10^5$ cfu/ml in the well (final volume of 200 μ l), the following dilutions were made from the McFarland stock:

20 All *H. influenzae* strains were diluted 1/100 in HTM.

All *S. pneumoniae* and *M. catarrhalis* were diluted 1:100 in cation supplemented Mueller Hinton broth containing 5% lysed horse blood.

25 INOCULATION OF PLATES: 100 μ l of the diluted inoculum is added to each 100 μ l of diluted drug in the sterile test plate. Total volume for the test is 200 μ l per well. Strains that have been diluted appropriately (see above) into microtiter wells will have a final inoculum of $2 \text{ to } 7 \times 10^5$ CFU/ ml. These cell inocula are confirmed on random plates by performing viability counts of the wells at zero time. This is easily done by removing 10 μ l from the well and diluting it in 10 ml of sterile, physiological saline (1:1000 dilution).

5 After vortexing, 100 μ l of the diluted suspension is spread on a blood agar plate or a chocolate agar plate in the case of *H. influenzae*. Following incubation, the presence of 50 colonies indicates an inoculum density of 5×10^5 CFU/ml. Cultures used for inocula into the
10 microtiter trays are streaked for single colonies and observed for typical colony morphology.

INCUBATION OF MICROTITER PLATES: After placing plastic lids on the plates, microtiter plates are incubated in plastic boxes in a controlled humidity
15 incubator to prevent evaporation from the wells. Plates are stacked no more than 4 high. All microtiter plates are incubated aerobically at 35 °C for 24 hours.

All plates are incubated and read after 24 hours and results are recorded only if the control drugs for
20 the NCCLS type strain *H. influenzae* ATCC 49766 and *S. pneumoniae* ATCC 49619 is within the published range (NCCLS, M100-S12, 2002).

Example 13

25 In Vivo Efficacy

The *in vivo* β -lactamase inhibitory activity of 6- β -HMPAS was determined for the β -lactamase (+) pathogens that were evaluated in our pre-clinical infection models. The data for these selected isolates indicated
30 that 6- β -HMPAS is generally equivalent to clavulanate for β -lactamases from the respiratory pathogens *H. influenzae* and *M. catarrhalis*.

Gerbil otitis media model: In this model, Mongolian gerbils were challenged with *S. pneumoniae* or *H.*
35 *influenzae*. Female Mongolian gerbils (50-60 g) were

5 challenged with log 5-6 CFU of *H. influenzae* or *S.*
pneumoniae delivered in a 50 μ L volume into the left
tympanic bulla. Eighteen hours post-challenge, a dose-
response therapeutic regimen was initiated (t.i.d.¹¹ for 2
days) with the combination of Amoxicillin and Prodrug 3
10 (7:1) delivering the dosage in a 500 μ L volume of 0.5%
methylcellulose vehicle. ED50s were calculated from
bacterial clearance data on day 4 post-challenge.

The amoxicillin/Prodrug 3 and Augmentin
combinations were equally effective in clearing this
15 pathogen with ED_{50s} of 6-10 mg/kg, and outcomes for the
7:1 and 14:1 combinations were equivalent. Amoxicillin
as a single agent failed against this pathogen.

Murine systemic infection model: In this model,
Female CF-1 or DBA/2 mice (18-20g) were challenged
20 intraperitoneally with log 2-6 CFU of *S. pneumoniae*, *S.*
aureus or *M. catarrhalis* suspended in broth, 10% mucin
or 3% Brewers yeast, respectively, and delivered in a
500 μ L volume. One hour post-challenge, a dose-
response therapeutic regimen was initiated (b.i.d. for 1
25 day) with the combination of Amoxicillin/Prodrug 3 (7:1)
delivering the dosage in a 200 μ L volume of 0.5%
methylcellulose vehicle. ED50s were calculated from the
survival data on day 4 post-challenge.

The combination of amoxicillin/Prodrug 3 was
30 effective in protecting mice from death from all of
these β -lactamase (+) strains. In general, the activity
of the amoxicillin/Prodrug 3 combination was comparable
to that of Augmentin (i.e. equivalent versus *H.*
influenzae and slightly less against *M. catarrhalis*).
35 The 7:1 combinations were generally more effective than

5 the 14:1 combinations. Data for the skin and skin structure pathogens *S. aureus*, *K. pneumoniae* and *E. coli* are also included in the following tables.

Murine pneumonia model: In this model, Female CF-1 (18-20g) were challenged intranasally with log 5-6 CFU
110 of *S. pneumoniae* delivered in a 40 μ L volume and eighteen hours post-challenge, a dose-response therapeutic regimen was initiated (b.i.d. for 2 days) with the combination of Amoxicillin/Prodrug 3 (7:1) delivering the dosage in a 200 μ L volume of 0.5%
15 methylcellulose vehicle. ED50s were calculated from the survival data on day 10 post-challenge.

Amoxicillin, amoxicillin/Prodrug 3 and Augmentin were equally effective against a penicillin-tolerant (PD₅₀s of 22-25 mg/kg) and penicillin-susceptible
20 pneumococcal strain (PD₅₀s of 2.7-3.3 mg/kg). Since penicillin-tolerant strains of pneumococci do not harbor a β -lactamase, the activity of amoxicillin is not improved (nor is it antagonized) by the presence of 6- β -HMPAS or clavulanate. The higher PD₅₀s noted with the
25 penicillin-tolerant strain relative to the penicillin-susceptible strain is consistent with the higher MIC.

In summary, the *in vivo* oral activity for the combination of amoxicillin/Prodrug 3 (7:1 and 14:1) was compared in a head-to-head fashion with Augmentin in a
30 gerbil otitis media model and mouse models of peritonitis and pneumonia. The amoxicillin/Prodrug 3 combination demonstrated comparable *in vivo* activity to that of Augmentin vs. respiratory tract pathogens (*H. influenzae*, *M. catarrhalis* and *S. pneumoniae*) and skin
35 and soft tissue pathogens (*S. aureus*, *E. coli* and *K.*

5 pneumoniae) in these models. The *in vivo* performance of the amoxicillin/Prodrug 3 was consistent with the *in vitro* activity of this combination when assayed at a 2:1 ratio in the MIC assay.

10 In Vivo Antibacterial Activity (Oral) vs. Respiratory Tract and Skin & Skin Structure Pathogens (ED50, mg/kg)

Pathogen	Amoxicillin	Prodrug 3	Amoxicillin/Prodrug 3 (7/1 ratio)	Augmentin (7/1 ratio)
Gerbil Otitis Media Model				
<i>Haemophilus influenzae</i> (54A1218) ²	>50	>25	8.9/1.3 ¹	9.9/1.4
Murine Systemic Model				
<i>Haemophilus influenzae</i> (54A1218)	>100	>25	9.8/1.4	13.4/1.9
<i>Moraxella catarrhalis</i> (87A1115)	>100	>100	37.6/5.4	12.6/1.8
<i>Staphylococcus aureus</i> (01A0400)	>100	>12.5	30.6/4.4	17.8/2.5
<i>Klebsiella pneumoniae</i> (53A0031)	>200	>25	20.2/2.9	13.0/1.8
<i>Escherichia coli</i> (51A0257)	>200	>100	62.2/8.9	146/20.8
Mouse Pneumonia Model				
<i>Streptococcus pneumoniae</i> (02J1095)	25	>25	21.8/3.1	21.8/3.1
<i>Streptococcus pneumoniae</i> (02J1016)	3.3	>25	2.66/0.38	2.66/0.38

¹The first value indicates the amoxicillin concentration while the second value is the beta-lactamase inhibitor.

²Numbers in parantheses indicate Pfizer strain ID

15 numbers.

5 In Vivo Antibacterial Activity (Oral) vs. Respiratory
Tract and Skin & Skin Structure Pathogens (ED50, mg/kg)

Pathogen	Amoxicillin	Prodrug 3	Amoxicillin/Prodrug 3 (14/1 ratio)	Augmentin (14/1 ratio)
Gerbil Otitis Media Model				
<i>Haemophilus influenzae</i> (54A1218)	>50	>25	10.5/0.73 ¹	5.8/0.4
Murine Systemic Model				
<i>Haemophilus influenzae</i> (54A1218)	>100	>25	12.3/0.88	37.9/2.7
<i>Moraxella catarrhalis</i> (87A1115)	>100	>100	42.5/3.0	23.6/1.7
<i>Staphylococcus aureus</i> (01A0400)	>100	>12.5	94.2/6.7	24.4/1.7
<i>Klebsiella pneumoniae</i> (53A0031)	>200	>25	23.4/1.7	23.4/1.7
<i>Escherichia coli</i> (51A0257)	>200	>100	134/9.6	196/14
Mouse Pneumonia Model				
<i>Streptococcus pneumoniae</i> (02J1095)	25	>25	23.6/1.7	17.8/1.3
<i>Streptococcus pneumoniae</i> (02J1016)	3.3	>25	1.6/0.11	1.8/0.12

¹The first value indicates the amoxicillin concentration while the second value is the beta-lactamase inhibitor.

²Numbers in parantheses indicate pfizer strain ID

10 numbers.


5

Claims

We claim:

1. A prodrug having the structure:

10



wherein R is H or methyl,
and solvates thereof.

15


2. A prodrug of Claim 1 selected from the group
consisting

of

- 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
20 acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-
(benzoyloxy)-methyl ester, 4,4-dioxide (2S,5R,6R),
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
acid,
25 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, -1-
(benzoyloxy)-ethyl ester, 4,4-dioxide (2S,5R,6R),
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic
acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-
30 (benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R),
and

- 5 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6- (hydroxymethyl) -3,3-dimethyl-7-oxo-, (1S) -1-
(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R) .

- 10 3. A prodrug having the structure:



and solvates thereof.

- 15 4. A pharmaceutical composition comprising:
(a) a prodrug of Claim 1, or a solvate thereof;
and
(b) at least one pharmaceutically acceptable
carrier, excipient or diluent.

20

5. A pharmaceutical composition of Claim 4 further
comprising a beta-lactam antibiotic.

- 25 6. A pharmaceutical composition of Claim 5 wherein
said beta-lactam antibiotic is amoxicillin.

7. A pharmaceutical composition of Claim 6 wherein
said

- 30 prodrug is 4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylic acid, 6- (hydroxymethyl) -3,3-dimethyl-7-
oxo-, (1R) -1- (benzoyloxy)ethyl ester, 4,4-dioxide

5 (2S,5R,6R) or a solvate thereof.

8. A pharmaceutical composition comprising:

(a) 4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic

10 acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-

(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or

a solvate thereof,

15 (b) amoxicillin, and

(c) a pharmaceutically acceptable carrier, excipient or diluent.

20 9. A method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal comprising administering to said mammal an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of
25 Claim 1, or a solvate thereof.

10. A method of Claim 9 wherein said beta-lactam antibiotic is amoxicillin.

30 11. A method of Claims 9-10 wherein said prodrug is 4-thia-1-

azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-

1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R)

35 or a

5 solvate thereof.

12. A method of treating a bacterial infection in a mammal by

110. administering to said mammal an effective amount of
a

beta-lactam antibiotic and an effectiveness-increasing

amount of a prodrug of Claim 1, or a solvate thereof.

15

13. A method of Claim 12 wherein said beta-lactam antibiotic is amoxicillin.

14. A method of Claims 12-13 wherein the prodrug is 4-

20 thia-

1-azabicyclo[3.2.0]heptane-2-carboxylic acid,
6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide (2S,5R,6R), or

a

25 solvate thereof.


15. A method of treating a bacterial infection in a mammal by

30 administering thereto a therapeutically effective
amount

of a pharmaceutical composition of Claims 4, 5 or 6 to a

mammal in need thereof.

35



(I)